Peripherally inserted central catheters (PICCs) are widely used for patients with cancer undergoing long-term chemotherapy. These catheters reduce the need for multiple venous punctures and protect ...

Neonatal patients often require long-term vascular access for the delivery of life-sustaining medications and nutrition. The peripherally inserted central catheter (PICC) offers several advantages ...

Amanda J. Ullman, Ph.D., from the University of Queensland in Brisbane, Australia, and colleagues conducted a randomized, controlled, superiority trial in three tertiary hospitals involving adults and ...

Several factors contraindicate PICC placement: lack of peripheral access, venous thrombosis, and end-stage renal disease. In addition, PICCs should not be used for frequent intermittent access or for ...

The use of peripherally inserted central venous catheters (PICC lines) has reduced the mortality and morbidity of premature newborns. The usual sites of insertion are the veins in the upper arms but ...

The Sherlock 3CG TCS comprises: a system console, including a control processor with display interface; a tip location sensor; a PowerPICC SOLO catheter with the Sherlock 3CG tip positioning stylet; a ...

Mumbai: BD (Becton, Dickinson and Company) India arm has announced the launch of Sherlock 3CG+, a technology designed to improve accuracy and efficiency in peripherally inserted central catheter (PICC ...

A peripherally-inserted central catheter (PICC) line, is a long, soft, flexible tube inserted into a vein in the upper arm. Doctors use it to administer intravenous (IV) drugs, for instance, in ...

NewsVoir New Delhi [India], October 29: BD (Becton, Dickinson and Company) India announced the national launch of Sherlock 3CG+ recently through a 4-city roadshow in Delhi, Mumbai, Chennai and Kolkata ...

PICCs have a relatively low complication rate, but there are several potentially serious issues related to their use. See Table 2 for signs and symptoms of complications. The first cause is alteration ...

The company identified 2 health economic studies in its submission (Adams 2013; Stewart 2013). Both studies were cost‑comparison studies from outside the UK healthcare system. The company noted that ...